Amundi Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Amundi increased its ANI Pharmaceuticals stake by 595.5% in the second quarter to 31,793 shares valued at approximately $2.6 million. Institutional investors collectively own 76.05% of the company.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting EPS of $2.21 versus the $2.04 consensus and revenue of $266.04 million, up 25.8% year over year. The company issued fiscal 2026 EPS guidance of $9.19–$9.69.
• Analyst sentiment remains positive but mixed, with five Buy ratings and four Holds producing a “Moderate Buy” consensus and an average price target of $105.57, compared with the stock’s reported price of $70.19.

Amundi boosted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 595.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,793 shares of the specialty pharmaceutical company's stock after buying an additional 27,222 shares during the period. Amundi owned approximately 0.14% of ANI Pharmaceuticals worth $2,632,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. California State Teachers Retirement System raised its position in shares of ANI Pharmaceuticals by 7,977.4% in the 2nd quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company's stock worth $164,200,000 after purchasing an additional 1,959,017 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in ANI Pharmaceuticals during the 3rd quarter valued at about $32,992,000. Ranger Investment Management L.P. bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at about $28,406,000. Deutsche Bank AG bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at about $26,775,000. Finally, Balyasny Asset Management L.P. raised its holdings in ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock worth $26,211,000 after buying an additional 276,233 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $70.19 on Monday. ANI Pharmaceuticals, Inc. has a 52 week low of $69.58 and a 52 week high of $99.39. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $1.61 billion, a P/E ratio of 15.13 and a beta of 0.45. The stock's 50-day moving average price is $77.26 and its 200-day moving average price is $78.21.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the company posted $1.80 EPS. The firm's revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $74.30, for a total value of $401,220.00. Following the sale, the chief executive officer directly owned 344,489 shares in the company, valued at approximately $25,595,532.70. The trade was a 1.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the transaction, the senior vice president owned 75,534 shares of the company's stock, valued at approximately $5,816,118. The trade was a 4.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 21,425 shares of company stock worth $1,687,370 over the last ninety days. 8.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ANIP has been the topic of several analyst reports. Canaccord Genuity Group dropped their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research note on Monday, August 10th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an "outperform" rating and a $104.00 price target for the company. Guggenheim decreased their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a report on Monday, August 10th. Wall Street Zen cut ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings downgraded ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $105.57.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.